Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 1/20 | 0.38 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.38 |
| ▸ | PSEN1 | P49768 | 7/20 | 0.38 |
| ▸ | PSEN2 | P49810 | 7/20 | 0.38 |
| ▸ | APH1B | Q8WW43 | 7/20 | 0.38 |
| ▸ | NCSTN | Q92542 | 7/20 | 0.38 |
| ▸ | APH1A | Q96BI3 | 7/20 | 0.38 |
| ▸ | PSENEN | Q9NZ42 | 7/20 | 0.38 |
| ▸ | MAOB | P27338 | 4/20 | 0.37 |
| ▸ | AR | P10275 | 3/20 | 0.35 |
| ▸ | PGR | P06401 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | NFE2L2 | Q16236 | 5/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4144782 | 1.00 | AURKA (0.38) | AURKAAURKBPSEN1PSEN2APH1B | |
| SCHEMBL4152147 | 0.86 | AURKA (0.42) | AURKAAURKBPSEN1PSEN2APH1B | |
| SCHEMBL4152145 | 0.86 | AURKA (0.42) | AURKAAURKBPSEN1PSEN2APH1B | |
| SCHEMBL4137897 | 0.81 | AURKA (0.49) | AURKAAURKB | |
| SCHEMBL4137894 | 0.81 | AURKA (0.49) | AURKAAURKB | |
| SCHEMBL4161483 | 0.81 | AURKA (0.41) | AURKAAURKBPSEN1PSEN2APH1B | |
| SCHEMBL4161488 | 0.81 | AURKA (0.41) | AURKAAURKBPSEN1PSEN2APH1B | |
| SCHEMBL4143959 | 0.80 | AURKA (0.49) | AURKAAURKBPSEN1PSEN2APH1B | |
| SCHEMBL4143953 | 0.80 | AURKA (0.49) | AURKAAURKBPSEN1PSEN2APH1B | |
| SCHEMBL4146279 | 0.78 | NTRK1 (0.42) | AURKAAURKBMEN1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090054397-A1 | PYRAZOLE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE COMPOUND | OHI NORIHITO | 2009-02-26 | — | — | US | disclosed |
| US-20090054397-A1 | PYRAZOLE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE COMPOUND | OHI NORIHITO | 2009-02-26 | — | — | US | disclosed |
| US-7429609-B2 | Pyrazole compound and medicinal composition containing the same | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2008-09-30 | — | — | US | disclosed |
| US-20050261339-A1 | Pyrazole compound and medicinal composition containing the same | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2005-11-24 | — | — | US | disclosed |
| US-20050208582-A1 | Pyrazole compounds and pharmaceutical compositions comprising the compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2005-09-22 | — | — | US | disclosed |
| EP-1510516-A1 | PYRAZOLE COMPOUND AND MEDICINAL COMPOSITION CONTAINING THE SAME | Eisai Co., Ltd. (JP) | 2005-03-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054397-A1 | PYRAZOLE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE COMPOUND | CNKSR1, NR3C2, CSNK2B | AURKA 726/4885AURKB 608/4885PSEN1 4577/4885 |
| US-20050261339-A1 | Pyrazole compound and medicinal composition containing the same | CNKSR1, NR3C2, CSNK2B | AURKA 710/4885AURKB 579/4885PSEN1 4733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.